Credence

Healthcare AI Spending Reaches $3.7B as Investment Shifts Toward Drug Discovery and Patient Care


Key Points

  • Healthcare AI spending reached $3.7 billion in 2026, a 2.5-fold increase, according to Menlo Ventures
  • Life sciences AI spending grew 23-fold to $700 million, with 51% of pharmaceutical companies deploying AI at scale
  • Spending on clinical copilots rose 5.5-fold to $550 million as investment shifts beyond administrative tools

Spending on artificial intelligence across the healthcare sector climbed to $3.7 billion in 2026, representing a 2.5-fold increase over the previous year, according to Menlo Ventures’ latest State of AI in Healthcare report. While early adoption centered largely on administrative applications such as clinical documentation, billing and coding, investment is increasingly moving toward drug discovery, clinical decision support and patient engagement.

The life sciences sector recorded the most dramatic growth, with AI spending increasing 23-fold, from $30 million to $700 million. The report found that 51% of pharmaceutical companies are now deploying AI at scale, compared with 15% a year earlier. Additionally, 84% of pharmaceutical R&D leaders expect AI to shorten drug development timelines by at least one year over the next three to five years. Although 93% of respondents anticipate an AI-discovered drug receiving its first approval within five years, only 28% expect that milestone within the next two years.

Menlo Ventures noted that AI could help address longstanding challenges in drug development, where bringing a new medicine to market typically takes more than a decade, costs billions of dollars and carries a clinical failure rate of approximately 90%. Greg Yap, venture partner at Menlo Ventures, said advances in AI models and autonomous agents are expanding the technology’s reach beyond administrative functions into research laboratories and clinical care. The report’s authors emphasized that the ultimate measure of progress will be whether AI helps produce effective medicines and improves patient outcomes.

AI adoption is also accelerating in clinical settings. Spending on clinical copilots increased 5.5-fold to $550 million, while patient engagement applications grew 4.5-fold to $450 million. By comparison, spending on clinical documentation tools increased 1.6-fold, and coding and billing applications grew 1.3-fold. The report also found that established healthcare technology providers are gaining ground in the clinical documentation market. Microsoft and Epic captured 68% of new AI scribe spending during the year, bringing incumbent providers’ share of the $950 million market to 46%, up from 33% in 2025. AI-native scribe companies continued to grow, but are increasingly expanding into adjacent applications such as prior authorization.

The report also identified changing dynamics in healthcare reimbursement. Payers accounted for just $150 million, or 4%, of external healthcare AI spending, but are increasingly affected by technology investments made by providers. In 2026, 43% of payers—and 57% of larger health plans—reported that providers’ use of AI-assisted coding had increased medical cost trends, compared with 23% the previous year. Prior authorization has consequently become a leading AI priority for payers, cited by 82% of respondents, up from 59% in 2025.

Now in its second year, the Menlo Ventures report examines AI purchasing and adoption across healthcare providers, health plans, pharmaceutical companies and biotechnology organizations. Its findings are based on a survey of 550 U.S. healthcare and life sciences executives involved in AI procurement, including 300 pharmaceutical and biotech executives, 150 provider technology decision-makers and 100 health plan and benefits administrators. Overall, the findings point to a healthcare AI market moving beyond workflow automation toward applications with the potential to influence drug development, clinical decision-making and the delivery of patient care.

Read the full report at www.menlovc.com.